While DNA vaccination using plasmid vectors is highly attractive, there is a need for further vector optimization regarding safety, stability, and efficiency. In this commentary, the authors [...]
MiniVector DNA transfects every cell type we have tried, including: aortic smooth muscle cells, suspension lymphoma cells and other difficult to transfect cell types.
Minivector DNA survives mechanical shear forces and survives enzymatic degradation by human serum nucleases.
DNA plasmid vector systems are stable and targeted genes can be regulated for several months by maintaining selection for the plasmid.
MiniVector delivery requires less DNA mass, which means less toxicity to cells.
MiniVectors are a cost-effective way to make small DNA circles, Twister really saved us a lot of time.
Designer genes that work: Twister Biotech's MiniVectors provide a new, safe and experimentally verified transfection system for primary and stem cells. Supercoiled DNA minicircles live at the intersection of theory and practice, and their use has great potential in the treatment of human disease.
Clinically, Minivectors should advance gene-targeting therapy specific for lymphoma, as well as other types of tumors, with little or no side effects on normal tissue in cancer patients.
C.E.O. and President of Twister Biotech, Dr. Zechiedrich holds the Kyle and Josephine Morrow Chair in Molecular Virology and Microbiology at Baylor College of Medicine. She is Professor in the departments of Molecular Virology and Microbiology, Biochemistry and Molecular Biology, and Pharmacology. Known internationally for her work on DNA structure/function, Dr. Zechiedrich has won numerous research and mentoring awards.
Dr. Matzuk is treasurer and a manager of Twister Biotech. He holds the Stuart A. Wallace Chair and Robert L. Moody, Sr. Chair in Pathology and Immunology and is the Director of the Center for Drug Discovery at Baylor College of Medicine. He is Professor in the Departments of Pathology and Immunology, Molecular and Cellular Biology, Molecular and Human Genetics, and Pharmacology.
More than 25 years experience at early stage Biotechnology companies encompassing both product/process development work and entrepreneurial business development work. Mr. Hebel now acts as a consultant to early stage companies developing and commercializing various biotechnology products based on cutting edge technologies.